eMedicine Specialties > Allergy and Immunology > Urticaria and Angioedema

Angioedema

Maurice Reid, MD, Staff Physician, Department of Emergency Medicine, University of Maryland Medical System
Brian Euerle, MD, FACEP, Associate Professor, Department of Emergency Medicine, Director of Emergency Ultrasound Program, University of Maryland School of Medicine; Mary Elizabeth Bollinger, DO, Associate Professor, Department of Pediatrics, Interim Chief, Division of Pediatric Pulmonology and Allergy, University of Maryland School of Medicine

Updated: Oct 20, 2008

Introduction

Background

Angioedema is characterized by painless, nonpruritic, nonpitting, and well-circumscribed areas of edema due to increased vascular permeability. Angioedema is most apparent in the head and neck, including the face, lips, floor of the mouth, tongue, and larynx, but edema may involve any portion of the body. In advanced cases, angioedema progresses to complete airway obstruction and death caused by laryngeal edema. Angioedema may involve the gastrointestinal tract, leading to intestinal wall edema, which results in symptoms such as colicky abdominal pain, nausea, vomiting, and diarrhea.

Angioedema can occur as a result of (1) hereditary angioedema (HAE); (2) acquired angioedema (AAE); (3) angioedema associated with allergic reactions, which is often associated with urticaria; (4) angioedema secondary to medications; and (5) idiopathic angioedema. In this article, the hereditary and acquired forms are discussed in detail. Angioedema induced by drugs, specifically angiotensin-converting enzyme (ACE) inhibitors, is explored briefly. Angioedema related to reactions mediated by immunoglobulin E is discussed in Anaphylaxis.

In 1888, Osler first described HAE when he treated a 24-year-old woman for chronic episodic attacks of edema. By interviewing the woman's 92-year-old grandfather, Osler learned that 5 successive generations of the family had a history of similar attacks. Osler proposed an inherited etiology and named the entity hereditary angioneurotic edema. In 1917, Crowder and Crowder determined that the condition is inherited as an autosomal dominant trait.

In 1963, Donaldson and Evans determined that an inherited deficiency of C1-esterase inhibitor (C1-INH) is at the core of this disease. C1-INH is one of the first components of the complement system. Classically, two phenotypic variants of this disorder have been described, and, more recently, a third type has been proposed.

In type I, which accounts for 80-85% of cases of HAE, serum levels of C1-INH (as determined by immunoassays) are low. In type II, patients have normal or elevated levels of C1-INH (as determined by immunoassay) but this C1-INH is dysfunctional (as determined by a functional assay). This deficiency in functioning C1-INH leads to autoactivation of the complement system and release of kininlike mediators, resulting in edema of the subcutaneous or submucosal tissues. The third, recently proposed variant has been labeled as HAE type 3. This type has been seen only in women and is thought to have an X-linked dominant mode of inheritance. These patients have normal C1-INH levels and function.

The exact mediators of this variant are unknown, but they are thought to act somewhere beyond kallikrein in the sequence of reactions.

AAE is a rare syndrome. Like HAE, AAE has 2 distinct forms. Type I is characterized by diminished levels of C1-INH secondary to its increased catabolism. Type I AAE is associated with lymphomas, chronic lymphocytic leukemia, and other lymphoproliferative diseases. Although the exact mechanism by which these lymphoproliferative diseases lead to angioedema is not clear, the underlying cause is thought to be the formation of immune complexes that increase consumption of C1-INH. In AAE type II, no lymphoproliferative or other underlying diseases are apparent but autoantibodies secreted by a subpopulation of B cells bind to the reactive center of C1-INH, altering its structure and regulatory capacity. Also worth noting is that autoantibodies have also been reported in type I AAE.

Approximately 94% of cases of angioedema presenting at the emergency department are drug induced. Most drug-induced angioedema is found in patients taking ACE inhibitors. As with HAE and AAE, life-threatening laryngeal edema and airway obstruction are major concerns. As many as 22% of patients with ACE inhibitor–induced angioedema require intubation, with an overall patient mortality rate of 11%. About 0.1-0.2% of patients treated with ACE inhibitors develop angioedema.

Pathophysiology

C1-INH is a serum alpha-2 globulin molecule and a member of the serpin family of protease inhibitors. The gene for C1-INH maps to chromosome 11. The gene is translated by hepatocytes as a single-chain glycoprotein containing 478 amino acids with a molecular weight of 105 kd. C1-INH is the only known plasma inhibitor of C1r and C1s, the activated proteases of the first component of the complement system. The complement system is a cascade reaction of approximately 20 components, which, when unopposed, results in increased vascular permeability and edema. C1-INH forms stable complexes with C1r and C1s by binding near or at their active sites, rendering them unable to cleave their natural substrates. Other targets of C1-INH include components of the coagulation cascade (eg, factors XIa, XIIa, XIIf), plasmin, and kallikrein, which is involved in the generation of bradykinin.

When C1-INH levels fall below 30% of the reference range, whether secondary to decreased production, dysfunction, or destruction, a domino effect occurs, leading to angioedema. Uncontrolled complement activation leads to the production of cleaved C2 kinin, a vasoactive molecule that causes angioedema. In addition, C1-INH is a major inhibitor of kallikrein, which converts high molecular weight–kinogen to bradykinin. The plasma bradykinin level rises substantially during acute attacks of hereditary, acquired, and ACE inhibitor–induced angioedema. Bradykinin has been shown to cause vasodilation, increased vascular permeability, and hypotension when injected intravenously into humans.

Bradykinin has been proposed as the primary mediator involved in angioedema caused by ACE inhibitors. ACE inhibitors work by blocking the action of the enzyme kinase II, which is involved in the conversion of angiotensin I to angiotensin II. Angiotensin II, a potent vasoconstrictor, is involved in the inactivation of bradykinin. When ACE inhibitors are used, angiotensin I is not converted to angiotensin II, leading to increased levels of bradykinin and angioedema. Angioedema is rare in patients taking angiotensin II AT1 receptor antagonists

Frequency

United States

Angioedema that is not secondary to HAE or AAE affects 10-20% of the population at some time in their lives. HAE is a rare condition, found in 1 per 150,000 persons. By some estimates, HAE may account for 15,000-30,000 emergency department visits yearly. AAE is even more rare; until 1997, fewer than 50 cases had been reported in the literature. The incidence of angioedema with the use of ACE inhibitors is reported to be 1-2 cases per 1000 persons.

International

Occurrence rates are believed to be similar to those in the US reports.

Mortality/Morbidity

Acute laryngeal edema is the major cause of angioedema-related mortality. Two thirds of people with HAE experience an episode of airway compromise. Unfortunately, 14-33% of persons die during these episodes because of airway compromise. In addition, life-threatening airway obstruction requiring intubation has been reported in as many as 22% of cases of ACE inhibitor–induced angioedema, leading to an overall mortality rate of 11%.

Race

No racial predilection is found in HAE or AAE. ACE inhibitor–induced angioedema is reported to be more common in African Americans than in individuals of other racial groups.

Sex

An equal distribution exists between males and females.

Age

The onset of HAE usually occurs by the first or second decade, but diagnosis in the fourth and fifth decades is not unusual. Most cases of AAE occur in individuals aged 50 years or older.

Clinical

History

Patients with HAE and those with AAE present with similar symptoms. Two thirds of the people with HAE present by age 13 years, and the onset of AAE usually occurs after the fourth decade.

• The classic symptom triad involves severe colicky abdominal pain, peripheral edema, and laryngeal edema in the absence of urticaria.
• Abdominal pain is accompanied by vomiting in 88% of patients and diarrhea in 22% of patients. Diarrhea is caused by intraluminal fluid in the edematous gut.
• Extremity swelling is found in 75% of patients.
• In 25% of patients, a prodromal rash resembling erythema marginatum occurs and blossoms over 1-4 days into true angioedema. This rash must be distinguished from urticaria. Urticaria is not associated with either HAE or AAE. If urticaria is present, consider a diagnosis other than HAE or AAE.
• The most dreaded complication of angioedema is complete airway obstruction caused by laryngeal edema. This type of airway swelling is usually less acute than that associated with anaphylaxis. Patients with upper airway involvement present with hoarseness and dysphagia, which may gradually progress to upper airway obstruction over a period of hours.
• In general, a course of angioedema develops fully within a few hours and fades in 48-72 hours, but it can persist for as long as 1 week.
• Other symptoms include urinary bladder retention, pleural effusion with cough, and pleuritic chest pain.
• Central nervous system symptoms (eg, headache, hemiparesis, seizures) may occur secondary to focal cerebral edema.

Physical

• Angioedema of the submucosal and subcutaneous tissue is tense, nonpitting, nonpruritic, and nonerythematous.
• Angioedema involves the extremities in 75% of patients and the face in 36% of patients.
• Abdominal pain may be severe. Examination of the abdomen may reveal bowel sounds that vary from normal to high-pitched. Pain is usually diffuse, with no rigidity or peritoneal signs.
• ACE inhibitor–induced angioedema most commonly affects the face but can affect any area of the body. In milder cases, a facial rash is present. When facial involvement progresses, edema of the soft palate, tongue, and larynx develops.

Causes

• Several precipitants of angioedema in HAE are known, including the following:
  • Mental and physical stress
  • Trauma
  • Dental or surgical procedures
  • Infections
  • Menstruation
  • Pregnancy
  • Oral contraceptives containing estrogens
• In AAE type I, diminished levels of C1-INH are associated with lymphoproliferative malignancies, including the following:
  • Chronic lymphocytic leukemia
  • Waldenström macroglobulinemia
  • Lymphosarcoma
  • Non-Hodgkin lymphoma
  • Essential cryoglobulinemia
  • Lymphocytic lymphoma
  • Myeloma
• No underlying disease is present in patients with type II AAE, but patients have autoantibodies directed at C1-INH. The result is depletion of C1-INH, precipitating angioedema.
• At the core of angioedema induced by ACE inhibitors is a decreased level of angiotensin II, which leads to increased levels of bradykinin. No correlation exists between the initiation of ACE inhibitor therapy and the clinical findings of angioedema. Although symptoms can occur within a few hours to several years, most patients (69-100%) are symptomatic within the first week of therapy. An otherwise stable patient developing angioedema after the ACE inhibitor dose is increased is not an unusual occurrence.

Differential Diagnoses

Anaphylaxis
Hymenoptera Stings

Other Problems to Be Considered

Allergic
Inhalants
Bites and stings
Natural rubber latex
Foods (eg, milk, eggs, peanuts, tree nuts, soy, wheat, seafood, sulfites)

Drugs
ACE inhibitors
Beta-lactam antibiotics
Sulfonamides
Aspirin/nonsteroidal anti-inflammatory drugs
Insulin
Dilantin
Streptokinase

Viral infections
Herpes simplex
Hepatitis B
Hepatitis C
Mononucleosis
Coxsackieviruses A and B

Bacterial infections
Dental caries/abscesses
Pharyngitis
Tonsillitis
Sinusitis
Otitis media
Upper respiratory infection
Urinary tract infection

Parasitic infections
Ascaris species
Strongyloides species
Echinococcus species
Toxocara species
Fasciola species
Filaria species
Schistosoma species

Workup

Laboratory Studies

• Laboratory evaluation of the complement system is essential to diagnose HAE or AAE.
  • In type I HAE, C1-INH and C4 levels are low. C4 levels are low during an attack; they may be normal in between attacks.
  • In type II HAE, which is characterized by normal levels of C1-INH that is dysfunctional, a functional or qualitative assay of C1-INH must be performed before the diagnosis can be excluded. C4 levels are low during an attack.
  • In type III HAE, C1-INH levels and function and C4 levels are normal at all times.
  • In HAE and AAE, C4 levels are low during angioedema episodes but may be normal in between episodes. C4 can be used for screening between angioedema episodes, with the understanding that a normal level does not rule out the diagnosis.
  • To differentiate between AAE and HAE, the C1q level should be measured. The hallmarks of AAE are low C1q, C2, C4, and C1-INH levels. In HAE, C1q levels are usually normal or only slightly decreased. Levels of C1q are rarely less than 50% of the normal values in HAE; in AAE, C1q levels are less than 10% of the normal values.
• Complete blood cell count: Leukocytosis should be absent. If leukocytosis is present, an infectious etiology should be sought. The white blood cell count may be elevated secondary to hemoconcentration.
• Electrolytes: Abnormalities may be present secondary to vomiting and diarrhea. Prerenal renal failure can also result from intravascular volume depletion.
• If time permits, a blood sample should be submitted for a type and crossmatch and for determination of the prothrombin time and activated partial thromboplastin time before surgical airway intervention is instituted.

Imaging Studies

• Plain abdominal films may show a "stacked coin" or "thumbprint" appearance of the intestines.
• A chest film may show pleural effusion.
• A soft tissue neck film may show soft tissue swelling.
• A CT scan image of the abdomen may show severe edema of the bowel wall.

Procedures

• Airway protection is the most important consideration in patients with angioedema. In cases of possible airway compromise, early intervention with intubation may be preferred. Intubation may be exceedingly difficult, and advanced techniques (eg, fiberoptic intubation) may be necessary. In severe cases of laryngeal edema, a surgical airway must be created via cricothyrotomy or tracheotomy.

Treatment

Medical Care

• Acute attacks
  • Voice changes (eg, hoarseness, stridor, muffling) are indications that airway intervention should be strongly considered. In urgent but nonemergent cases, orotracheal intubation is the preferred method. When laryngeal edema is severe, a surgical airway must be created via cricothyrotomy or tracheotomy.
  • Attain intravenous access with large-bore line.
  • Fluid resuscitation may be necessary.
  • Continuously monitor vital signs.
  • Epinephrine, corticosteroids, and antihistamines are not effective in patients with HAE, AAE, and ACE inhibitor–induced angioedema. These agents are recommended as second-line therapy. In cases of angioedema due to allergic causes, these medications are first-line therapies (see Anaphylaxis).
  • Vapor-heated C1-INH concentrate (recommended dosage 500-2000 U IV) is the first-line therapy for acute attacks of HAE or AAE, and was recently approved by the FDA in the United States for routine prophylaxis. When vapor-heated C1-INH concentrate is unavailable, fresh frozen plasma (FFP) (2 U IV) may be used. FFP may worsen an attack by providing substrates of complement that may exacerbate angioedema; however, this treatment is being used by many centers in this situation, given the lack of other available therapies, and most do not report any difficulties.
  • Other treatment options for acute attacks include antifibrinolytic agents (eg, tranexamic acid, epsilon-aminocaproic acid). These agents probably act by inhibiting plasmin, which plays a role in initiating the complement cascade. Tranexamic acid is not approved for treatment of HAE or AAE in the United States.
• Long-term prophylaxis
  • Long-term prophylaxis is indicated when a person is experiencing more than 2 attacks per month or if the airway is compromised continuously. Some authors recommend that long-term prophylaxis be considered in any patient with HAE affecting any organ system, regardless of the number of previous episodes.
  • The agents of choice are the synthetic androgens danazol and stanozolol. Androgenic agents are effective because they induce messenger-RNA synthesis in the liver and directly increase C1-INH levels. Stanozolol and danazol have the same efficacy, but stanozolol has less masculinizing potential. In pediatric patients, antifibrinolytic agents are recommended as the first choice because of their favorable safety profile.
  • Epsilon-aminocaproic acid and tranexamic acid have been used successfully to prevent bouts of HAE and AAE.
• Short-term prophylaxis
  • Dental procedures or elective surgery of the oropharyngeal region often precipitates acute bouts of HAE or AAE. Therefore, short-term prophylaxis is necessary.
  • A combination of FFP, vapor-heated C1-INH concentrate (if available), and androgen therapy is the regimen of choice.
• Treatment of the underlying disorder associated with AAE (ie, malignancy) usually results in correction of the abnormality.
• Patients who have had angioedema related to an ACE inhibitor must be cautioned against resuming that drug or using another drug in the class at any time. In addition, it is becoming recognized that these patients may be at risk for angioedema if taking an angiotensin receptor antagonist; their use should be considered only if no other option is available.
• Therapies currently under investigation for HAE and AAE include the following (For more information, see United States Hereditary Angioedema Association.):
  • C1 inhibitor concentrates (Pharming and Lev Pharmaceuticals) are currently undergoing clinical testing.
  • A kallikrein inhibitor, DX-88 (Dyax/Genzyme), is currently undergoing an open-label trial for use in HAE and AAE.
  • B2 bradykinin receptor antagonist, Icatibant (Jerini Pharmaceutical), is also undergoing clinical trials.

Consultations

Consultation with an allergist or an immunologist is recommended in the management of HAE or AAE.

Medication

The goal of medical treatment for HAE and AAE is to either increase levels of C1-INH (eg, C1-INH concentrate, androgens) or to limit mediators of the complement cascade (eg, antifibrinolytic agents).

Androgens

Induce messenger-RNA synthesis in the liver and directly increase C1-INH. Agents of choice for long- and short-term prophylaxis.

Danazol (Danocrine)

Increases levels of C4 component of complement and reduces attacks associated with angioedema.

Dosing

Adult

50-600 mg/d PO (usually 200 mg PO tid)
Short-term prophylaxis: 200 mg PO tid for 5-10 d preoperatively and 3 d postoperatively

Pediatric

Not established

Interactions

Decreases insulin requirements and increases effects of anticoagulants (monitor PT); carbamazepine levels may increase

Contraindications

Documented hypersensitivity; seizure disorders, renal or hepatic insufficiency, pregnancy, breastfeeding, conditions influenced by edema

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in cardiac insufficiency, epilepsy, migraines, undiagnosed abnormal vaginal bleeding; women should be observed for virilization

Stanozolol (Winstrol)

Synthetic androgen with immunosuppressive properties.

Dosing

Adult

1-4 mg/d PO
Short-term prophylaxis: 1 mg qid for 5-10 d preoperatively and 3 d postoperatively

Pediatric

Not established

Interactions

Increases hypoprothrombinemic effects of oral anticoagulants and hypoglycemic effects of insulin and sulfonylureas

Contraindications

Documented hypersensitivity; nephrosis; breast or prostate cancer; pregnancy, breastfeeding

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

May cause peliosis hepatitis, liver cell tumors, and blood lipid changes with increased risk of arteriosclerosis; caution in cardiac, renal, or hepatic disease and epilepsy; women should be observed for virilization

Hemostatic agents

Mechanism of action in the treatment of HAE and AAE is unknown. Most likely related to inhibition of plasmin.

Aminocaproic acid (Amicar)

Inhibits fibrinolysis via inhibition of plasminogen activator substances and, to a lesser degree, through antiplasmin activity. Main problem is that the thrombi that form during treatment are not lysed, and effectiveness is uncertain.

Dosing

Adult

8 g IV q4h, then 16 g/d in acute attacks;
6-10 g/d PO maintenance

Pediatric

8-10 g/d PO

Interactions

Coadministration with estrogens may cause an increase in clotting factors, leading to a hypercoagulable state

Contraindications

Documented hypersensitivity; evidence of active intravascular clotting process; DIC

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not administer unless a definite diagnosis of hyperfibrinolysis is made; caution in cardiac, hepatic, or renal disease and thrombosis and myonecrosis

Tranexamic acid (Cyklokapron)

Alternative to aminocaproic acid. Inhibits fibrinolysis by displacing plasminogen from fibrin.

Dosing

Adult

Up to 8 g PO/IV for acute attacks, 1-2 g PO for maintenance

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in renal impairment or thrombosis

Vasopressors

In angioedema caused by drugs and foods, catecholamines improve vascular permeability, vascular resistance, and bronchodilation. Less effective in HAE and AAE, but used as second-line therapy.

Epinephrine (EpiPen, Adrenalin)

Has alpha-agonist effects that include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Beta-agonist effects include bronchodilatation, chronotropic cardiac activity, and positive inotropic effects.

Dosing

Adult

0.3-0.5 mL IM/SC of 1:1000 dilution

Pediatric

0.01 mL/kg IM/SC of 1:1000 dilution; not to exceed 0.5 mL

Interactions

Increases toxicity of beta- and alpha-blocking agents and that of halogenated inhalational anesthetics; effects potentiated by TCAs, levothyroxine, certain antihistamines, and MAOIs

Contraindications

Documented hypersensitivity; cardiac arrhythmia or angle-closure glaucoma; not for use during labor (may delay second stage of labor)

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in elderly persons and persons with prostatic hypertrophy, hypertension, cardiovascular disease, diabetes mellitus, hyperthyroidism, and cerebrovascular insufficiency; rapid IV infusions may cause death from cerebrovascular hemorrhage or cardiac arrhythmia

Antihistamines

Histamine causes increased vascular permeability. Blocking this effect at the receptor level provides symptomatic relief.

Diphenhydramine (Benadryl)

For symptomatic relief of symptoms caused by release of histamine.

Dosing

Adult

50 mg PO/IV/IM q6h; infuse slowly

Pediatric

1 mg/kg PO/IV/IM q6h; not to exceed 50 mg; infuse slowly

Interactions

Potentiates effect of CNS depressants; due to alcohol content, do not administer syrup to patients taking medications that can cause disulfiramlike reactions

Contraindications

Documented hypersensitivity; MAOIs

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

May exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, and urinary tract obstruction; caution in pregnancy, breastfeeding and premature infants

Ranitidine (Zantac)

H2 antagonist that, when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.

Dosing

Adult

50 mg IV over 5 min

Pediatric

0.5 mg/kg IV over 5 min

Interactions

May decrease effects of ketoconazole and itraconazole; may alter serum levels of ferrous sulfate, diazepam, nondepolarizing muscle relaxants, and oxaprozin; may increase PT with concurrent use of warfarin

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in renal or liver impairment; if changes in renal function occur during therapy, consider adjusting dose or discontinuing treatment

Glucocorticoids

Anti-inflammatory actions inhibit the late-phase response to allergens. Inhibit inflammatory cell proliferation and release of mediators that can cause increased capillary permeability and bronchoconstriction observed in anaphylaxis.

Methylprednisolone (Solu-Medrol, Depo-Medrol)

Steroids ameliorate delayed effects of anaphylactoid reactions and may limit biphasic anaphylaxis.

Dosing

Adult

125 mg IV

Pediatric

1-2 mg/kg IV

Interactions

Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels; phenobarbital, phenytoin, and rifampin may decrease levels (adjust dose); monitor patients for hypokalemia when taking concurrently with diuretics; concurrent use with cyclosporine may cause convulsions; decreased clearance with concurrent use of ketoconazole; possible increase in PT with warfarin coadministration

Contraindications

Documented hypersensitivity; viral, fungal, or tubercular skin infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications of glucocorticoid use

Serine Proteinase Inhibitors (serpins)

Used for routine prophylaxis against angioedema attacks.

C1 inhibitor, human (Cinryze)

C1 inhibitor is a normal constituent of human blood and is one of the serine proteinase inhibitors (serpins). Regulates activation of pathway for complement and intrinsic coagulation. Also regulates fibrinolytic system. Available as a sterile, lyophilized preparation derived from human plasma. Specific activity is 4-9 U/mg protein. One unit corresponds to the mean quantity of C1 inhibitor present in 1 mL of normal fresh plasma. Indicated for routine prophylaxis against angioedema attacks in adolescents and adults with hereditary angioedema.

Dosing

Adult

1000 U IV infused over 10 min; repeat every 3-4 d

Pediatric

Neonates and children: Not established
Adolescents: Administer as in adults

Interactions

Data limited; none reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Severe hypersensitivity may occur and result in hives, urticaria, chest tightness, wheezing, hypotension, and/or anaphylaxis (discontinue and administer epinephrine if warranted); thrombotic events have been reported with high doses; as with all products derived from human blood, universal precautions for infection transmission should be used; common adverse effects (ie, >5%) include URTIs, sinusitis, rash, and headache

Follow-up

Further Inpatient Care

• Patients with oropharyngeal involvement should be admitted to either an intensive care unit or an intermediate care unit, depending on the severity of the angioedema (ie, lip vs tongue and soft palate involvement).
• If available, an in-house ear, nose, and throat specialist should be notified of the patient's condition and the possibility that a surgical airway or use of equipment for direct laryngoscopy may be needed. In this regard, an anesthesiologist should also be notified of the potential for airway compromise.
• All hospitalized patients should be monitored continuously with pulse oximetry.
• Continued analgesia and fluid resuscitation are also concerns in patients with HAE or AAE.

Further Outpatient Care

• Patients with HAE or AAE should follow up with an allergist and an immunologist as soon as possible.

Inpatient & Outpatient Medications

• Long-term prophylaxis with androgens is needed for patients with monthly attacks or a history of airway compromise.
• In children, long-term prophylaxis with aminocaproic acid reduces attacks by 80%.
• Prophylaxis is needed before any dental or oropharyngeal procedure (ie, 5-10 d preoperatively and 3 d postoperatively). Shortly before the intervention, FFP should be administered.
• Before emergent procedures, purified C1-INH may be administered. In addition, women who are pregnant may receive C1-INH before delivery. This has no effect on C1-INH levels in the newborn because C1-INH does not cross the placenta.

Complications

• The most dreaded complication of angioedema is complete airway obstruction caused by laryngeal edema. This type of airway swelling is usually less severe than that associated with anaphylaxis. Patients with upper airway involvement present with hoarseness and dysphagia, which may gradually progress to upper airway obstruction over a period of hours.

Patient Education

• More information is available from the United States Hereditary Angioedema Association.
• For excellent patient education resources, visit eMedicine's Allergy Center and Skin, Hair, and Nails Center. Also, see eMedicine's patient education article Hives and Angioedema.

Miscellaneous

Medicolegal Pitfalls

• Failure to consider the diagnosis, especially in patients with the classic triad of abdominal pain, peripheral edema, and laryngeal edema
• Failure to intervene early by securing the airway in patients with oropharyngeal involvement
• Failure to instruct patients who have had ACE inhibitor–related angioedema that they have a lifelong prohibition from taking the drug again as well as any others in the class is a pitfall. This information must also be communicated to the patient's primary care provider.

Multimedia

Media file 1: The mechanism of angioedema resulting from C1-esterase inhibitor deficiency.

Media file 2: Man with angioedema involving the lips.

References

1. Agah R, Bandi V, Guntupalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med. Jul 1997;23(7):793-6. [Medline].

2. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24(8):599-606. [Medline].

3. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. Sep 2004;114(3 Suppl):S51-131. [Medline].

4. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. Jul 15 2000;356(9225):213-7. [Medline].

5. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. Sep 2004;114(3):629-37. [Medline].

6. Ebo DG, Stevens WJ. Hereditary angioneurotic edema: review of the literature. Acta Clin Belg. Jan-Feb 2000;55(1):22-9. [Medline].

7. Farkas H, Harmat G, Füst G, et al. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. Jun 2002;13(3):153-61. [Medline].

8. Fay A, Abinun M. Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency). J Clin Pathol. Apr 2002;55(4):266-70. [Medline].

9. Frigas E. Angioedema with acquired deficiency of the C1 inhibitor: a constellation of syndromes. Mayo Clin Proc. Oct 1989;64(10):1269-75. [Medline].

10. Gaboriau HP, Solomon JW. Angioneurotic edema. J La State Med Soc. Feb 1997;149(2):50-2. [Medline].

11. Heymann WR. Acquired angioedema. J Am Acad Dermatol. Apr 1997;36(4):611-5. [Medline].

12. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?. Drug Saf. 2002;25(2):73-6. [Medline].

13. Kyrmizakis DE, Papadakis CE, Liolios AD, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg. Dec 2004;130(12):1416-9.

14. Markovic SN, Inwards DJ, Frigas EA, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med. Jan 18 2000;132(2):144-50. [Medline].

15. Moore GP, Hurley WT, Pace SA. Hereditary angioedema. Ann Emerg Med. Oct 1988;17(10):1082-6. [Medline].

16. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. Nov 12 2001;161(20):2417-29. [Medline].

17. Rodgers GK, Galos RS, Johnson JT. Hereditary angioedema: case report and review of management. Otolaryngol Head Neck Surg. Mar 1991;104(3):394-8. [Medline].

18. Shah UK, Jacobs IN. Pediatric angioedema: ten years' experience. Arch Otolaryngol Head Neck Surg. Jul 1999;125(7):791-5. [Medline].

19. Sim TC, Grant JA. Hereditary angioedema: its diagnostic and management perspectives. Am J Med. Jun 1990;88(6):656-64. [Medline].

20. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. Jun 20 1996;334(25):1630-4. [Medline].

21. Zirkle M, Bhattacharyya N. Predictors of airway intervention in angioedema of the head and neck. Otolaryngol Head Neck Surg. Sep 2000;123(3):240-5. [Medline].

Keywords

angioneurotic edema, oedema, laryngeal edema, hereditary angioedema, HAE, acquired angioedema, AAE, allergic reactions, hereditary angioneurotic edema, airway obstruction, swelling

Contributor Information and Disclosures

Author

Maurice Reid, MD, Staff Physician, Department of Emergency Medicine, University of Maryland Medical System
Maurice Reid, MD is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Brian Euerle, MD, FACEP, Associate Professor, Department of Emergency Medicine, Director of Emergency Ultrasound Program, University of Maryland School of Medicine
Brian Euerle, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Institute of Ultrasound in Medicine, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Mary Elizabeth Bollinger, DO, Associate Professor, Department of Pediatrics, Interim Chief, Division of Pediatric Pulmonology and Allergy, University of Maryland School of Medicine
Mary Elizabeth Bollinger, DO is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, and American College of Allergy, Asthma and Immunology
Disclosure: Merck Honoraria Speaking and teaching; Merck Consulting fee Consulting; Novartis Honoraria Speaking and teaching

Medical Editor

Stephen C Dreskin, MD, PhD, Director of Allergy, Asthma, and Immunology Practice, Professor of Medicine, Departments of Internal Medicine and Immunology, University of Colorado Health Sciences Center
Stephen C Dreskin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association for the Advancement of Science, American Association of Immunologists, American Association of Neuropathologists, American Association of Ophthalmic Pathologists, American Association of Oral and Maxillofacial Surgeons, American College of Allergy, Asthma and Immunology, Clinical Immunology Society, and Joint Council of Allergy, Asthma and Immunology
Disclosure: Genentech Consulting fee Consulting

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Samuel R Marney, Jr, MD, Director, Associate Professor, Department of Internal Medicine, Division of Allergy and Immunology, Vanderbilt University School of Medicine
Samuel R Marney, Jr, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, American College of Physicians, and Tennessee Medical Association
Disclosure: Nothing to disclose.

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Michael A Kaliner, MD, Clinical Professor of Medicine, George Washington University School of Medicine; Chief, Section of Allergy and Immunology, Washington Hospital Center; Medical Director, Institute for Asthma and Allergy
Michael A Kaliner, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American Society for Clinical Investigation, American Thoracic Society, and Association of American Physicians
Disclosure: Abbott Consulting fee Consulting; Alcon Consulting fee Consulting; Glaxo Consulting fee Consulting; Greer Consulting fee Consulting; Sanofi Consulting fee Consulting; Schering Consulting fee Consulting; Teva  Consulting; Meda Honoraria Speaking and teaching

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)